MX2019003569A - Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. - Google Patents
Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.Info
- Publication number
- MX2019003569A MX2019003569A MX2019003569A MX2019003569A MX2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A MX 2019003569 A MX2019003569 A MX 2019003569A
- Authority
- MX
- Mexico
- Prior art keywords
- bavituximab
- methods
- glycoprotein
- treating cancer
- levels
- Prior art date
Links
- 229950007843 bavituximab Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000003556 assay Methods 0.000 title 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000002203 pretreatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400589P | 2016-09-27 | 2016-09-27 | |
| US201662406727P | 2016-10-11 | 2016-10-11 | |
| US201762480994P | 2017-04-03 | 2017-04-03 | |
| US201762507580P | 2017-05-17 | 2017-05-17 | |
| PCT/US2017/053370 WO2018064013A1 (en) | 2016-09-27 | 2017-09-26 | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003569A true MX2019003569A (es) | 2020-07-22 |
Family
ID=66538296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003569A MX2019003569A (es) | 2016-09-27 | 2017-09-26 | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3519827A1 (enExample) |
| JP (1) | JP2019537619A (enExample) |
| KR (1) | KR20190057303A (enExample) |
| CN (1) | CN109863402A (enExample) |
| AU (1) | AU2017334698A1 (enExample) |
| CA (1) | CA3037008A1 (enExample) |
| MX (1) | MX2019003569A (enExample) |
| WO (1) | WO2018064013A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018187227A1 (en) * | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents |
| EP3837546A1 (en) * | 2018-08-13 | 2021-06-23 | Regeneron Pharmaceuticals, Inc. | Therapeutic protein selection in simulated in vivo conditions |
| EP4021940A1 (en) * | 2020-05-12 | 2022-07-06 | Astrazeneca AB | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| CN114716547B (zh) * | 2022-05-18 | 2023-11-21 | 珠海丽禾医疗诊断产品有限公司 | 一种包括抗原结合结构域的结合蛋白及其生产方法和应用 |
| WO2024065243A1 (en) * | 2022-09-28 | 2024-04-04 | University Of Macau | Drug for treatment of breast cancer and application thereof |
| CN119555937B (zh) * | 2025-01-26 | 2025-05-20 | 杭州奥泰生物技术股份有限公司 | 一种犬虫媒病五联抗体检测卡及其制备方法和试剂盒 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| BR9911882A (pt) | 1998-07-13 | 2005-02-15 | Univ Texas | Processo de tratamento de câncer empregando anticorpos a aminofosfolipìdios |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| AU2012201537B2 (en) * | 2002-07-15 | 2014-06-05 | Board Of Regents, The University Of Texas System | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer |
| US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7572448B2 (en) | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
| DK1853631T3 (en) | 2005-01-24 | 2016-03-29 | Univ Texas | Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| BRPI0820298A8 (pt) | 2007-11-09 | 2018-05-08 | Affitech Res As | composições e métodos de anticorpos anti-vegf |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| CA2940823C (en) | 2014-02-27 | 2017-03-28 | Board Of Regents, The University Of Texas System | Methods and compositions for isolating exosomes |
| EP3309174B1 (en) | 2014-07-11 | 2022-05-11 | Ventana Medical Systems, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
-
2017
- 2017-09-26 CN CN201780058161.8A patent/CN109863402A/zh active Pending
- 2017-09-26 MX MX2019003569A patent/MX2019003569A/es unknown
- 2017-09-26 WO PCT/US2017/053370 patent/WO2018064013A1/en not_active Ceased
- 2017-09-26 JP JP2019538088A patent/JP2019537619A/ja active Pending
- 2017-09-26 CA CA3037008A patent/CA3037008A1/en not_active Abandoned
- 2017-09-26 EP EP17791768.9A patent/EP3519827A1/en not_active Withdrawn
- 2017-09-26 KR KR1020197008828A patent/KR20190057303A/ko not_active Ceased
- 2017-09-26 AU AU2017334698A patent/AU2017334698A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018064013A1 (en) | 2018-04-05 |
| CN109863402A (zh) | 2019-06-07 |
| KR20190057303A (ko) | 2019-05-28 |
| CA3037008A1 (en) | 2018-04-05 |
| WO2018064013A8 (en) | 2019-05-23 |
| AU2017334698A1 (en) | 2019-03-21 |
| WO2018064013A9 (en) | 2018-07-05 |
| JP2019537619A (ja) | 2019-12-26 |
| EP3519827A1 (en) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003569A (es) | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. | |
| MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| SV2017005380A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
| BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MY209360A (en) | Anti-cd47 and anti-cd20 based treatment of blood cancer | |
| CR20160132A (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
| EA201790716A1 (ru) | Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr | |
| EA201792545A1 (ru) | Способы и наборы для лечения депрессии | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| BR112017021312A2 (pt) | tratamento de câncer de pulmão com inibidores de glutaminase | |
| MX2019011657A (es) | Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer. | |
| BR112015017403A2 (pt) | biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória | |
| NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| NZ746609A (en) | Ilt7 binding molecules and methods of using the same | |
| NZ754522A (en) | Oxabicycloheptanes for modulation of immune response |